The Androgen Receptor (AR) is critical for the development of prostate cancer (PC) and remains a critical target in both metastatic prostate cancer (mPC) and metastatic castration-resistant prostate cancer (mCRPC). This evidence concerns the gene AR and prostate carcinoma.